Barinthus Biotherapeutics Statistics

Total Valuation

BRNS has a market cap or net worth of $57.02 million. The enterprise value is -$48.01 million.

Market Cap	57.02M
Enterprise Value	-48.01M

Important Dates

The next estimated earnings date is Monday, November 11, 2024, before market open.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

BRNS has 39.41 million shares outstanding. The number of shares has increased by 2.59% in one year.

Current Share Class	n/a
Shares Outstanding	39.41M
Shares Change (YoY)	+2.59%
Shares Change (QoQ)	+0.69%
Owned by Insiders (%)	7.89%
Owned by Institutions (%)	27.13%
Float	27.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.36
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.08.

Current Ratio	8.46
Quick Ratio	7.92
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,794.89

Financial Efficiency

Return on equity (ROE) is -34.13% and return on invested capital (ROIC) is -21.37%.

Return on Equity (ROE)	-34.13%
Return on Assets (ROA)	-19.70%
Return on Capital (ROIC)	-21.37%
Revenue Per Employee	n/a
Profits Per Employee	-$490,654
Employee Count	130
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-1.47M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.78% in the last 52 weeks. The beta is -0.58, so BRNS's price volatility has been lower than the market average.

Beta (5Y)	-0.58
52-Week Price Change	-67.78%
50-Day Moving Average	1.28
200-Day Moving Average	1.94
Relative Strength Index (RSI)	59.32
Average Volume (20 Days)	29,891

Short Selling Information

Short Interest	3,975
Short Previous Month	4,564
Short % of Shares Out	0.02%
Short % of Float	n/a
Short Ratio (days to cover)	0.11

Income Statement

Revenue	n/a
Gross Profit	-43.95M
Operating Income	-68.21M
Pretax Income	-65.25M
Net Income	-63.79M
EBITDA	-65.60M
EBIT	-68.21M
Earnings Per Share (EPS)	-$1.65

Full Income Statement

Balance Sheet

The company has $117.77 million in cash and $12.57 million in debt, giving a net cash position of $105.20 million or $2.67 per share.

Cash & Cash Equivalents	117.77M
Total Debt	12.57M
Net Cash	105.20M
Net Cash Per Share	$2.67
Equity (Book Value)	156.79M
Book Value Per Share	4.00
Working Capital	116.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$54.62 million and capital expenditures -$383,000, giving a free cash flow of -$55.01 million.

Operating Cash Flow	-54.62M
Capital Expenditures	-383,000
Free Cash Flow	-55.01M
FCF Per Share	-$1.40

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BRNS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.59%
Shareholder Yield	-2.59%
Earnings Yield	-111.87%
FCF Yield	-96.47%

Analyst Forecast

The average price target for BRNS is $4.00, which is 176.51% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	176.51%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BRNS has an Altman Z-Score of 0.03 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.03
Piotroski F-Score	1